Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial

The UK Medicines and Healthcare Products Regulatory Agency has given Pulmatrix (NSDQ:PULM) the go-ahead to launch its first-in-human study for an inhaled formulation of the anti-fungal drug, itraconazole.
The company is evaluating its drug, Pulmazole, as a treatment for allergic bronchopulmonary aspergillosis in patients with asthma.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial appeared first on MassDevice.

Source: Mass Device - January 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news